Summit Therapeutics Inc.

Summit Therapeutics Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicinal therapies. The company aims to improve quality of life, increase potential duration of life, and address serious unmet medical needs. Its pipeline of product candidates focuses on oncology. Summit's lead development candidate is ivonescimab, a bispecific antibody designed to combine immunotherapy (PD-1 blockade) with anti-angiogenesis (anti-VEGF) effects in a single molecule. On December 5, 2022, Summit entered into a License Agreement with Akeso, Inc. and its affiliates, through which it in-licensed intellectual property rights for ivonescimab. This agreement granted Summit rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan. The transaction closed in January 2023. On June 3, 2024, Summit amended the License Agreement with Akeso to expand its territories to include Latin America (Mexico and all countries in Central and South America), the Middle East, and Africa. The company's operations are currently focused on the development of ivonescimab.